Fumonisin B1 reduces the development of multiple organ failure induced by zymosan in mice

Shock

Volumn 31, Issue 2, 2009, Pages 170-177

  Cuzzocrea, Salvatore ^a,b   Genovese, Tiziana ^b   Mazzon, Emanuela ^b   Esposito, Emanuela ^b   Crisafuili, Concetta ^a   Paola, Rosanna Di ^b   Bramanti, Placido ^b   Salvemini, Daniela ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ceramide; Cytokines; Inflammation; NO; Zymosan induced multiple organ failure

Indexed keywords

3 NITROTYROSINE; CERAMIDE; FUMONISIN B1; MYELOPEROXIDASE; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL MIGRATION; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; LIVER INJURY; LUNG INJURY; MALE; MORTALITY; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PANCREAS INJURY; PERITONEUM EXUDATE; POLYMORPHONUCLEAR CELL; RISK REDUCTION; STAINING; WEIGHT REDUCTION;

ANIMALS; CYTOKINES; FUMONISINS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICE; MULTIPLE ORGAN FAILURE; NITRIC OXIDE; PERITONITIS; PEROXIDASE; SHOCK; TIME FACTORS; TREATMENT OUTCOME; ZYMOSAN;

EID: 59649117355     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31817fbd4a     Document Type: Article

References (35)

1. Goris RJ, van Bebber IP, Mollen RM, Koopman JP: Does selective decontamination of the gastrointestinal tract prevent multiple organ failure? An experimental study. Arch Surg 126:561-565, 1991.
2. Demling R, Nayak U, Ikegami K, LaLonde C: Comparison between lung and liver lipid peroxidation and mortality after zymosan peritonitis in the rat. Shock 2:222-227, 1994.
3. van Bebber IP, Boekholz WK, Goris RJ, Schillings PH, Dinges HP, Bahrami S, Redl H, Schlag G: Neutrophil function and lipid peroxidation in a rat model of multiple organ failure. J Surg Res 47:471-175, 1989.
4. von Asmuth EJ, Maessen JG, van der Linden CJ, Buurman WA: Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model. Scand J Immunol 32:313-319, 1990.
5. Petit F, Bagby GJ, Lang CH: Tumor necrosis factor mediates zymosan-induced increase in glucose flux and insulin resistance. Am J Physiol 268:E219-E228, 1995.
6. Damas J, Remacle-Volon G, Bourdon V: Platelet-activating factor and the vascular effects of zymosan in rats. Eur J Pharmacol 231:231-236, 1993.
7. Deitch EA, Ma WJ, Ma L, Berg RD, Specian RD: Protein malnutrition predisposes to inflammatory-induced gut-origin septic states. Ann Surg 211:560-567; discussion 567-568, 1990.
8. Mainous MR, Ertel W, Chaudry IH, Deitch EA: The gut: a cytokine-generating organ in systemic inflammation? Shock 4:193-199, 1995.
9. Thomsen LL, Ching LM, Baguley BC: Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Res 50:6966-6970, 1990.
10. Zingarelli B, Squadrito F, Altavilla D, Calapai G, Campo GM, Calo M, Saitta A, Caputi AP: Evidence for a role of nitric oxide in hypovolemic hemorrhagic shock. J Cardiovasc Pharmacol 19:982-986, 1992.
11. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 87:1620-1624, 1990.
12. Cuzzocrea S, de Sarro G, Costantino G, Mazzon E, Laura R, Ciriaco E, de Sarro A, Caputi AP: Role of interleukin-6 in a non-septic shock model induced by zymosan. Eur Cytokine Netw 10:191-203, 1999.
13. Ward PA, Till GO, Kunkel R, Beauchamp C: Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest 72: 789-801, 1983.
14. Fantone JC, Ward PA: Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol 107:395-418, 1982.
15. Kolesnick R, Fuks Z: Radiation and ceramide-induced apoptosis. Oncogene 22:5897-5906, 2003.
16. Goggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, Brade L, Brade H, Ehlers S, Slutsky AS, Schutze S, et al.: PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 10:155-160, 2004.
17. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM: Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 11:491-498, 2005.
18. Delogu G, Famularo G, Amati F, Signore L, Antonucci A, Trinchieri V, Di Marzio L, Cifone MG: Ceramide concentrations in septic patients: a possible marker of multiple organ dysfunction syndrome. Crit Care Med 27:2413-2417, 1999.
19. Dobrowsky RT, Kolesnick RN: Analysis of sphingomyelin and ceramide levels and the enzymes regulating their metabolism in response to cell stress. Methods Cell Biol 66:135-165, 2001.
20. Claus RA, Bunck AC, Bockmeyer CL, Brunkhorst FM, Losche W, Kinscherf R, Deigner HP: Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J 19:1719-1721, 2005.
21. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, Gallily R, Edwards CK 3rd, Schuchman EH, Fuks Z, Kolesnick R: Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 186:1831-1841, 1997.
22. Mullane KM, Westlin W, Kraemer R: Activated neutrophils release mediators that may contribute to myocardial injury and dysfunction associated with ischemia and reperfusion. Ann N Y Acad Sci 524:103-121, 1988.
23. Schlag G, Redl H, Hallstrom S: The cell in shock: the origin of multiple organ failure. Resuscitation 21:137-180, 1991.
24. Thiemermann C, Ruetten H, Wu CC, Vane JR: The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 116:2845-2851, 1995.
25. Ruetten H, Thiemermann C: Effect of calpain inhibitor I, an inhibitor of the proteolysis of I kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br J Pharmacol 121:695-704, 1997.
26. Cuzzocrea S, Mazzon E, Di Paola R, Patel NS, Genovese T, Muia C, De Sarro A, Thiemermann C: Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther 311:1272-1280, 2004.
27. Matsunaga T, Kotamraju S, Kalivendi SV, Dhanasekaran A, Joseph J, Kalyanaraman B: Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells: protective role of endogenous nitric oxide. J Biol Chem 279:28614-28624, 2004.
28. Perrotta C, De Palma C, Falcone S, Sciorati C, Clementi E: Nitric oxide, ceramide and sphingomyelinase-coupled receptors: a tale of enzymes and messengers coordinating cell death, survival and differentiation. Life Sci 77:1732-1739, 2005.
29. Huwiler A, Dorsch S, Briner VA, van den Bosch H, Pfeilschifter J: Nitric oxide stimulates chronic ceramide formation in glomerular endothelial cells. Biochem Biophys Res Commun 258:60-65, 1999.
30. Huwiler A, Boddinghaus B, Pautz A, Dorsch S, Franzen R, Briner VA, Brade V, Pfeilschifter J: Superoxide potently induces ceramide formation in glomerular endothelial cells. Biochem Biophys Res Commun 284: 404-410, 2001.
31. Pautz A, Franzen R, Dorsch S, Boddinghaus B, Briner VA, Pfeilschifter J, Huwiler A: Cross-talk between nitric oxide and superoxide determines ceramide formation and apoptosis in glomerular cells. Kidney Int 61:790-796, 2002.
32. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Ndengele M, Salvemini D: Superoxide-related signaling cascade mediates nuclear factor-kappaB activation in acute inflammation. Antioxid Redox Signal 6:699-704, 2004.
33. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 53:135-159, 2001.
34. Volman TJ, Hendriks T, Verhofstad AA, Kullberg BJ, Goris RJ: Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome. Shock 17:468-472, 2002.
35. Jansen MJ, Hendriks T, Hermsen R, Van der Meer JW, Goris RJ: A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome. Cytokine 10: 904-910, 1998.